HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUNEONCO-B

6.000

-0.110-1.80%

Volume:974.80K

Turnover:5.83M

Market Cap:2.59B

PE:-9.87

High:6.280

Open:6.160

Low:5.850

Close:6.110

52wk High:16.800

52wk Low:3.430

Shares:432.00M

HK Float Shares:420.48M

Volume Ratio:0.47

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.608

ROE:-29.87%

ROA:-13.80%

PB:2.86

PE(LYR):-9.87

PS:14.65

Loading ...

Overview Company News Filings

IMMUNEONCO-B Soars Over 17% as Science Journal Validates CD47 Bispecific Antibody's Clinical Potential

Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone

IMMUNEONCO-B (01541) Administers First Dose in Phase III Trial of IMM0306 for Relapsed/Refractory Follicular Lymphoma

IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma

Bulletin Express

ImmuneOnco doses first patient in Phase III IMM0306 trial for relapsed/refractory follicular lymphoma

ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives

Simply Wall St.

Instil Bio FY2025 net loss per share narrows 6.06% to $10.70; revenue was not reported

BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million

IMMUNEONCO-B Reports Fiscal Year Performance: Revenue Jumps 108.09% to 154 Million Yuan

ImmuneOnco Posts FY-2025 Loss Narrowing to RMB219 Million; Revenue Doubles on Up-fronts and Milestones

Bulletin Express

ImmuneOnco Biopharmaceuticals Shanghai Inc - FY Loss Attributable RMB218.6 Mln

THOMSON REUTERS

ImmuneOnco Biopharmaceuticals FY2025; revenue rises to CNY 154 million due to Axion payments

ImmuneOnco Biopharmaceuticals FY2025 operating loss narrows 30.74% to RMB219 million; revenue jumps 108.23% to RMB154 million due to Axion Bio payments

IMMUNEONCO-B (01541) Completes Enrollment of 133 Patients for Interim Analysis in Phase III Trial of IMM01 (Tidapaxic) as First-Line Treatment for Chronic Myelomonocytic Leukemia

ImmuneOnco completes enrollment of 133 patients for interim analysis in Phase III IMM01 CMML trial

IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy

IMMUNEONCO-B (01541) Schedules 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend

Bulletin Express

ImmuneOnco Biopharmaceuticals schedules board meeting to approve annual results and consider final dividend

IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval

ImmuneOnco Biopharmaceuticals Receives Regulatory Nod to Begin Human Trials of IMM0306S

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/01541/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"IMMUNEONCO-B","latestPrice":6,"timestamp":1776407662459,"preClose":6.11,"halted":0,"volume":974800,"delay":0,"changeRate":-0.01800327332242231,"floatShares":420477305,"shares":432000000,"eps":-0.6078951776391487,"marketStatus":"Trading","change":-0.11,"latestTime":"04-17 14:35:29","open":6.16,"high":6.28,"low":5.85,"amount":5828436,"amplitude":0.070376,"askPrice":6,"askSize":2800,"bidPrice":5.97,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-0.6434513106708726,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1776413400000},"marketStatusCode":2,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":6.11,"openAndCloseTimeList":[[1776389400000,1776398400000],[1776402000000,1776412800000]],"volumeRatio":0.465651,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":420477305,"roa":"-13.80%","roe":"-29.87%","lyrEps":-0.607895,"volumeRatio":0.465651,"shares":432000000,"dividePrice":0,"high":6.28,"amplitude":0.070376,"preClose":6.11,"low":5.85,"week52Low":3.43,"pbRate":"2.86","psRate":"14.65","week52High":16.8,"institutionHeld":0,"latestPrice":6,"committee":-0.647059,"eps":-0.6078951776391487,"divideRate":0,"volume":974800,"delay":0,"ttmEps":-0.6434513106708726,"open":6.16,"prevYearClose":5.83,"prevWeekClose":4.74,"prevMonthClose":4.44,"prevQuarterClose":4.44,"fiveDayClose":4.74,"twentyDayClose":4.78,"sixtyDayClose":6.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2026-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774402200000,"name":null,"time":"","dateTimestamp":1774368000000,"actualEps":null},{"date":"2025-08-26","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"Post Market","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2026-04-16","current":-9.497325,"percent":0.539658,"low":-30.003263,"twenty":-17.760834,"median":-11.822955,"eighty":-6.032692,"high":-2.993766,"avg":-12.664924,"sd":7.128866,"marketCap":2636512016},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555},{"date":"2025-05-16","current":-8.311097,"twenty":-24.799485,"median":-12.12195,"eighty":-5.751942,"marketCap":2843007711},{"date":"2025-05-23","current":-11.289802,"twenty":-24.776462,"median":-11.940532,"eighty":-5.771038,"marketCap":3873496179},{"date":"2025-05-30","current":-15.223569,"twenty":-24.763734,"median":-11.970101,"eighty":-5.797425,"marketCap":5246123111},{"date":"2025-06-06","current":-16.623143,"twenty":-24.617548,"median":-12.331836,"eighty":-5.827424,"marketCap":5743038499},{"date":"2025-06-13","current":-15.603079,"twenty":-24.258649,"median":-12.701975,"eighty":-5.862056,"marketCap":5392753881},{"date":"2025-06-20","current":-14.878015,"twenty":-24.00727,"median":-12.82804,"eighty":-5.90109,"marketCap":5132076957},{"date":"2025-06-27","current":-13.023121,"twenty":-23.933348,"median":-12.837907,"eighty":-5.91626,"marketCap":4504823106},{"date":"2025-07-04","current":-14.906416,"twenty":-23.89321,"median":-12.895238,"eighty":-5.935244,"marketCap":5156515418},{"date":"2025-07-11","current":-12.022018,"twenty":-23.818294,"median":-12.972072,"eighty":-5.957179,"marketCap":4154538489},{"date":"2025-07-18","current":-12.975089,"twenty":-23.597552,"median":-12.895238,"eighty":-5.971632,"marketCap":4480384645},{"date":"2025-07-25","current":-12.316929,"twenty":-23.410778,"median":-12.839078,"eighty":-5.984465,"marketCap":4268584643},{"date":"2025-08-01","current":-12.109688,"twenty":-23.260279,"median":-12.895238,"eighty":-5.992729,"marketCap":4170830796},{"date":"2025-08-08","current":-13.046774,"twenty":-23.142239,"median":-12.972072,"eighty":-6.013995,"marketCap":4504823106},{"date":"2025-08-15","current":-15.594562,"twenty":-23.052783,"median":-12.982136,"eighty":-6.023266,"marketCap":5376461574},{"date":"2025-08-22","current":-14.245172,"twenty":-22.717488,"median":-13.011166,"eighty":-6.052989,"marketCap":4895838493},{"date":"2025-08-29","current":-13.416028,"twenty":-22.485479,"median":-13.022379,"eighty":-6.061027,"marketCap":4439653875},{"date":"2025-09-05","current":-17.224047,"twenty":-22.314693,"median":-13.032106,"eighty":-6.075447,"marketCap":5694161576},{"date":"2025-09-12","current":-15.065483,"twenty":-22.014704,"median":-13.063177,"eighty":-6.087386,"marketCap":4989519263},{"date":"2025-09-19","current":-14.903882,"twenty":-21.818428,"median":-13.085834,"eighty":-6.113201,"marketCap":4932496186},{"date":"2025-09-26","current":-13.980202,"twenty":-21.168438,"median":-13.096763,"eighty":-6.121719,"marketCap":4614796184},{"date":"2025-10-03","current":-19.067762,"twenty":-21.059976,"median":-13.099741,"eighty":-6.122985,"marketCap":6309196195},{"date":"2025-10-10","current":-15.483575,"twenty":-20.658991,"median":-13.109708,"eighty":-6.128239,"marketCap":5115784649},{"date":"2025-10-17","current":-12.892469,"twenty":-20.520951,"median":-13.123492,"eighty":-6.17051,"marketCap":4256365412},{"date":"2025-10-24","current":-11.824326,"twenty":-20.411262,"median":-13.104868,"eighty":-6.183537,"marketCap":3905144639},{"date":"2025-10-31","current":-11.96327,"twenty":-20.170656,"median":-13.098863,"eighty":-6.223751,"marketCap":3956925563},{"date":"2025-11-07","current":-10.312858,"twenty":-19.984772,"median":-13.08999,"eighty":-6.257081,"marketCap":3408910790},{"date":"2025-11-14","current":-10.296734,"twenty":-19.520389,"median":-13.071805,"eighty":-6.311268,"marketCap":3413225867},{"date":"2025-11-21","current":-8.92105,"twenty":-19.161835,"median":-13.046774,"eighty":-6.362869,"marketCap":2955827710},{"date":"2025-11-28","current":-9.407815,"twenty":-19.096653,"median":-13.027047,"eighty":-6.414675,"marketCap":3128430788},{"date":"2025-12-05","current":-8.666243,"twenty":-19.073975,"median":-13.014894,"eighty":-6.44644,"marketCap":2886786479},{"date":"2025-12-12","current":-8.404571,"twenty":-19.037964,"median":-12.986335,"eighty":-6.450097,"marketCap":2804800017},{"date":"2025-12-19","current":-8.049417,"twenty":-18.988805,"median":-12.975089,"eighty":-6.476679,"marketCap":2692608016},{"date":"2025-12-24","current":-7.972984,"twenty":-18.926105,"median":-12.9589,"eighty":-6.505915,"marketCap":2675347709},{"date":"2026-01-02","current":-7.788017,"twenty":-18.753419,"median":-12.908879,"eighty":-6.55197,"marketCap":2623566785},{"date":"2026-01-09","current":-8.075331,"twenty":-18.727145,"median":-12.839078,"eighty":-6.58869,"marketCap":2727128632},{"date":"2026-01-16","current":-7.93455,"twenty":-18.70371,"median":-12.833897,"eighty":-6.596451,"marketCap":2688292939},{"date":"2026-01-23","current":-6.093671,"twenty":-18.557812,"median":-12.82514,"eighty":-6.55197,"marketCap":2062606782},{"date":"2026-01-30","current":-5.748685,"twenty":-18.530718,"median":-12.736832,"eighty":-6.440954,"marketCap":1954729858},{"date":"2026-02-06","current":-5.480977,"twenty":-18.467104,"median":-12.547098,"eighty":-6.250095,"marketCap":1868428319},{"date":"2026-02-13","current":-5.764322,"twenty":-18.451463,"median":-12.334661,"eighty":-6.129552,"marketCap":1976305243},{"date":"2026-02-20","current":-5.709616,"twenty":-18.447248,"median":-12.324382,"eighty":-6.122036,"marketCap":1954729858},{"date":"2026-02-27","current":-5.173921,"twenty":-18.36049,"median":-12.246119,"eighty":-6.086335,"marketCap":1790756934},{"date":"2026-03-06","current":-5.567891,"twenty":-18.158064,"median":-12.065853,"eighty":-6.054191,"marketCap":1911579088},{"date":"2026-03-13","current":-6.117869,"twenty":-18.015354,"median":-11.997781,"eighty":-6.054191,"marketCap":2110072628},{"date":"2026-03-20","current":-5.927628,"twenty":-17.916043,"median":-11.941476,"eighty":-6.046952,"marketCap":2036716320},{"date":"2026-03-27","current":-7.775976,"twenty":-17.807771,"median":-11.897801,"eighty":-5.998519,"marketCap":1924524319},{"date":"2026-04-02","current":-8.241979,"twenty":-17.7975,"median":-11.83436,"eighty":-6.013995,"marketCap":2049661551},{"date":"2026-04-10","current":-8.161679,"twenty":-17.786583,"median":-11.824288,"eighty":-6.015601,"marketCap":2045346474},{"date":"2026-04-16","current":-10.516229,"twenty":-17.760834,"median":-11.822955,"eighty":-6.032692,"marketCap":2636512016}],"updateTime":1776386885522},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1110703736","title":"IMMUNEONCO-B Soars Over 17% as Science Journal Validates CD47 Bispecific Antibody's Clinical Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=1110703736","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110703736?lang=en_us&edition=fundamental","pubTime":"2026-04-13 10:26","pubTimestamp":1776047180,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) surged more than 17%, with gains reaching 17.09% at the time of writing to trade at HK$5.55. Turnover amounted to HK$11.44 million. A recent article by PharmaCube highlighted...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK1161","BK4588","BK4585","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139291031","title":"Stock Track | IMMUNEONCO-B Soars 5.15% in Intraday Trading on Phase III Clinical Trial Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1139291031","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139291031?lang=en_us&edition=fundamental","pubTime":"2026-03-31 10:02","pubTimestamp":1774922528,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B's stock price surged 5.15% during intraday trading on Tuesday, following a significant announcement from the company regarding its lead drug candidate.The biopharmaceutical company...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112797571","title":"IMMUNEONCO-B (01541) Administers First Dose in Phase III Trial of IMM0306 for Relapsed/Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1112797571","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112797571?lang=en_us&edition=fundamental","pubTime":"2026-03-31 00:31","pubTimestamp":1774888274,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced that the first patient has been dosed in a Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for the treatment of relapsed/refractory...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161","BK4134","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177793692","title":"IMMUNEONCO-B Initiates Phase III Study: First Patient Dosed with Dual-Targeting Therapy IMM0306 for Relapsed/Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1177793692","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177793692?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:48","pubTimestamp":1774882102,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) announced that the first patient has been dosed in its Phase III clinical trial evaluating IMM0306 in combination with lenalidomide for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623349471","title":"ImmuneOnco doses first patient in Phase III IMM0306 trial for relapsed/refractory follicular lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2623349471","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623349471?lang=en_us&edition=fundamental","pubTime":"2026-03-30 22:40","pubTimestamp":1774881627,"startTime":"0","endTime":"0","summary":"ImmuneOnco dosed first patient in Phase III trial of IMM0306 combined with lenalidomide for relapsed or refractory follicular lymphoma.IMM0306 is a CD47-CD20 bispecific designed to block CD47-SIRPα signaling while preferentially binding CD20 to target malignant B cells with reduced toxicity.No clinical results were reported in announcement, with no presentation timing disclosed.ImmuneOnco holds global intellectual property rights plus commercial rights for IMM0306.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely respons","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL7VczxW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622990822","title":"ImmuneOnco Biopharmaceuticals (SEHK:1541) Losses Narrow 23.6% Annually Challenging Bearish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622990822","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622990822?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:16","pubTimestamp":1774617408,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) (SEHK:1541) has laid out its FY 2025 scorecard with first half revenue of C¥44.0 million and a basic EPS loss of C¥0.37, alongside net income loss excluding extra items of C¥152.6 million. The company has reported revenue of C¥0.7 million in 1H 2024, C¥78.8 million in 2H 2024 and C¥44.0 million in 1H 2025. Over the same periods, basic EPS losses were C¥0.44, C¥0.39 and C¥0.37 respectively, providing a basis to assess how effectively revenue is being...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/immuneonco-biopharmaceuticals-sehk1541-losses-narrow-236-ann","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/immuneonco-biopharmaceuticals-sehk1541-losses-narrow-236-ann","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622233458","title":"Instil Bio FY2025 net loss per share narrows 6.06% to $10.70; revenue was not reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2622233458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622233458?lang=en_us&edition=fundamental","pubTime":"2026-03-27 19:02","pubTimestamp":1774609357,"startTime":"0","endTime":"0","summary":"Instil Bio filed a Form 8-K reporting Q4 and full-year 2025 results, with net loss per share of $1.21 in Q4 and $10.70 for FY 2025.Non-GAAP net loss per share was $0.97 in Q4 and $6.91 for FY 2025.Cash, cash equivalents, restricted cash and marketable securities totaled $76.3 million at year-end, down 33.71%, and the company said this is expected to fund its current operating plan beyond 2027.In January 2026, Axion Bio discontinued clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco for AXN-2510 and AXN-27M, with Bronson Crouch saying the company is evaluating acquisitions and in-licensing opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instil Bio Inc. published the orig","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4Wz8mL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","TIL","BK4505","BK4139","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077735","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077735","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077735?lang=en_us&edition=fundamental","pubTime":"2026-03-25 23:09","pubTimestamp":1774451352,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Inc Posts FY Loss Attributable RMB218.6 MillionMarch 25  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:FY LOSS ATTRIBUTABLE RMB218.6 MILLIONFY REVENUE RMB154.3 MILLIONFurther company coverage: 1541.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145478217","title":"IMMUNEONCO-B Reports Fiscal Year Performance: Revenue Jumps 108.09% to 154 Million Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1145478217","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145478217?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:34","pubTimestamp":1774449262,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced its annual results for the period ending December 31, 2025. The company achieved revenue of 154 million yuan, representing an increase of 108.09% compared to the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120157750","title":"ImmuneOnco Posts FY-2025 Loss Narrowing to RMB219 Million; Revenue Doubles on Up-fronts and Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=1120157750","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120157750?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:21","pubTimestamp":1774448512,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. reported FY-2025 revenue of RMB154.29 million, up 108.0% year-on-year, driven mainly by near-term and milestone payments from a 2024 out-licensing and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074244","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc -  FY Loss Attributable RMB218.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074244?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:15","pubTimestamp":1774448133,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D0WG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074298","title":"ImmuneOnco Biopharmaceuticals FY2025; revenue rises to CNY 154 million due to Axion payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074298","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074298?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:15","pubTimestamp":1774448124,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals  highlighted continued advancement of its oncology pipeline, positioning IMM01 and IMM2510 as potential differentiated assets in crowded immuno-oncology markets.IMM01’s Phase III program in first-line CMML enrolled 104 subjects by Dec. 31, 2025, and later reached 132 subjects for interim analysis on March 23, 2026, supporting a clearer path toward later-stage value inflection.IMM2510 monotherapy expanded to 183 enrolled patients by Dec. 31, 2025, and the company said additional data are slated for release at 2026 ASCO, which could shape competitive positioning in solid tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4wlGw6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622074268","title":"ImmuneOnco Biopharmaceuticals FY2025 operating loss narrows 30.74% to RMB219 million; revenue jumps 108.23% to RMB154 million due to Axion Bio payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074268","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074268?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:15","pubTimestamp":1774448115,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals FY2025 operating loss narrows 30.74% to RMB219 million; revenue jumps 108.23% to RMB154 million due to Axion Bio payments. FY2025 revenue rose 108.2% to RMB154 million on higher near-term payments from the Axion Bio license and collaboration agreement.FY2025 research and development expenses were little changed at RMB322 million.Management said it planned to continue advancing its drug candidates and expand its overseas footprint.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 25, 2026, and is solely responsible ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL13ngmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118018723","title":"IMMUNEONCO-B (01541) Completes Enrollment of 133 Patients for Interim Analysis in Phase III Trial of IMM01 (Tidapaxic) as First-Line Treatment for Chronic Myelomonocytic Leukemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1118018723","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118018723?lang=en_us&edition=fundamental","pubTime":"2026-03-23 07:24","pubTimestamp":1774221862,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) announced the successful completion of patient recruitment for the interim analysis of its Phase III clinical trial evaluating IMM01 (Tidapaxic) as a first-line treatment for...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","III","01541","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621448917","title":"ImmuneOnco completes enrollment of 133 patients for interim analysis in Phase III IMM01 CMML trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2621448917","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621448917?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:16","pubTimestamp":1774217818,"startTime":"0","endTime":"0","summary":"ImmuneOnco completed enrollment of 133 patients for an interim analysis in a Phase III trial of IMM01  as a first-line treatment for chronic myelomonocytic leukemia.Interim results have not been presented in the announcement and are expected to be presented in the future.IMM01 is a CD47-targeting SIRPα-Fc fusion protein designed to block CD47/SIRPα signaling and engage activating Fcγ receptors on macrophages.The company said IMM01’s CD47-binding domain was engineered to avoid binding to human red blood cells.IMM01 in combination with azacitidine received orphan-drug designation from the US FDA for first-line CMML in November 2023.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the origi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260322:nNDL6b3hWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127803256","title":"IMMUNEONCO-B (01541) Surges Over 10% Following Phase II Clinical Trial Approval for IMM0306 in Primary Membranous Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=1127803256","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127803256?lang=en_us&edition=fundamental","pubTime":"2026-03-18 10:54","pubTimestamp":1773802458,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) saw its shares rise more than 10%. At the time of writing, the stock was up 10.46%, trading at HK$5.28, with a turnover of HK$7.03 million. On March 17, the company announced...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","BK1161","BK4585","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176347215","title":"IMMUNEONCO-B (01541) Schedules 25 Mar 2026 Board Meeting to Approve FY 2025 Results and Consider Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1176347215","media":"Bulletin Express","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176347215?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:22","pubTimestamp":1773397347,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B, 01541) has convened a board meeting for 25 March 2026. Directors will review and approve the consolidated annual results for the year...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619193730","title":"ImmuneOnco Biopharmaceuticals schedules board meeting to approve annual results and consider final dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193730","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193730?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:05","pubTimestamp":1773396345,"startTime":"0","endTime":"0","summary":"ImmuneOnco will hold a board meeting on 25 March 2026 to consider and approve its annual results for the year ended 31 December 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL47rRZw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","01541"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126203337","title":"IMMUNEONCO-B (01541) Extends Rally, Surges Over 6% After IMM0306S Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1126203337","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126203337?lang=en_us&edition=fundamental","pubTime":"2026-03-09 13:56","pubTimestamp":1773035775,"startTime":"0","endTime":"0","summary":"IMMUNEONCO-B (01541) has risen more than 6%, extending its recent gains. At the time of writing, the stock was up 6.09% to HK$4.70, with a turnover of HK$10.3795 million. The increase follows the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","BK4585","01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618611258","title":"ImmuneOnco Biopharmaceuticals Receives Regulatory Nod to Begin Human Trials of IMM0306S","url":"https://stock-news.laohu8.com/highlight/detail?id=2618611258","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618611258?lang=en_us&edition=fundamental","pubTime":"2026-03-09 12:49","pubTimestamp":1773031770,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said it received Chinese regulatory approval to begin human trials of IMM0306S in systemic lupus erythematosus, according to a Hong Kong bourse filing Friday.Shares of the pharmaceutical firm gained over 2% in late morning trade Monday.The announcement came amid \"unusual movements\" in the company's stock price.ImmuneOnco said outside the regulatory approval to begin human trials of IMM0306S, there were no undisclosed matters that would warrant an unusual movement in its stock's price.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}